X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DISHMAN PHARMA NATCO PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 33.0 25.1 131.7% View Chart
P/BV x 16.8 3.3 502.6% View Chart
Dividend Yield % 0.7 0.7 102.4%  

Financials

 NATCO PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DISHMAN PHARMA
Mar-16
NATCO PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs877374 234.2%   
Low Rs424129 328.5%   
Sales per share (Unadj.) Rs223.4197.8 113.0%  
Earnings per share (Unadj.) Rs31.121.2 146.5%  
Cash flow per share (Unadj.) Rs40.334.7 116.0%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.8 96.8%  
Book value per share (Unadj.) Rs219.5179.9 122.0%  
Shares outstanding (eoy) m33.0780.69 41.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.3 228.8%   
Avg P/E ratio x20.911.9 176.4%  
P/CF ratio (eoy) x16.17.2 222.8%  
Price / Book Value ratio x3.01.4 211.8%  
Dividend payout %16.19.4 170.6%   
Avg Mkt Cap Rs m21,50420,306 105.9%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,1285,355 21.1%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m7,38915,961 46.3%  
Other income Rs m167265 63.0%   
Total revenues Rs m7,55616,226 46.6%   
Gross profit Rs m1,7934,103 43.7%  
Depreciation Rs m3041,091 27.9%   
Interest Rs m366944 38.8%   
Profit before tax Rs m1,2902,334 55.3%   
Minority Interest Rs m460-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309624 49.5%   
Profit after tax Rs m1,0271,711 60.0%  
Gross profit margin %24.325.7 94.4%  
Effective tax rate %23.926.7 89.6%   
Net profit margin %13.910.7 129.7%  
BALANCE SHEET DATA
Current assets Rs m3,68111,018 33.4%   
Current liabilities Rs m3,1239,517 32.8%   
Net working cap to sales %7.69.4 80.4%  
Current ratio x1.21.2 101.8%  
Inventory Days Days89110 81.0%  
Debtors Days Days5935 168.5%  
Net fixed assets Rs m7,68516,304 47.1%   
Share capital Rs m331161 204.9%   
"Free" reserves Rs m6,67012,907 51.7%   
Net worth Rs m7,25914,516 50.0%   
Long term debt Rs m9554,189 22.8%   
Total assets Rs m11,95729,805 40.1%  
Interest coverage x4.53.5 130.3%   
Debt to equity ratio x0.10.3 45.6%  
Sales to assets ratio x0.60.5 115.4%   
Return on assets %11.78.9 130.8%  
Return on equity %14.211.8 120.1%  
Return on capital %20.717.5 118.2%  
Exports to sales %39.424.8 158.8%   
Imports to sales %5.73.7 152.6%   
Exports (fob) Rs m2,9083,956 73.5%   
Imports (cif) Rs m421596 70.6%   
Fx inflow Rs m3,4454,952 69.6%   
Fx outflow Rs m703697 100.9%   
Net fx Rs m2,7434,255 64.5%   
CASH FLOW
From Operations Rs m1,4402,786 51.7%  
From Investments Rs m-1,089-1,529 71.2%  
From Financial Activity Rs m-353-941 37.5%  
Net Cashflow Rs m-1316 -0.5%  

Share Holding

Indian Promoters % 52.0 61.4 84.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.7 211.9%  
FIIs % 16.6 12.7 130.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 22.1 117.6%  
Shareholders   25,395 46,261 54.9%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 22, 2017 03:36 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS